Targeting treatments for extraprostatic and oligometastatic prostate cancer with curative intent

The moderator of a well-known, prostate cancer-specific Internet forum recently wrote to us, stating,

There has been some assumption on the part of users of internet patient forums that the [newer and] more sensitive scans can be useful to detect major tumors that can be removed laparoscopically or treated with radiation, and that this would be beneficial.

… READ MORE …

SHIVA trial studying response to molecular targeting strategy for drug therapy

At the upcoming meeting of the European Cancer Congress (ECC2013), starting on Friday, September 27 in Amsterdam, The Netherlands, Dr. Christophe Le Tourneau, Head of the Phase I Program at the Institut Curie, Paris, France, will give attendees an initial report on progress of the so-called SHIVA trial. … READ MORE …

Taregted therapy and companion diagnostic: the AEZS-108 story

Here’s a clear signal that prostate cancer is entering the world of targeted therapeutics associated with specific companion diagnostics: the Canadian company Aeterna Zentaris has announced a partnership to develop a companion diagnostic to identify patients likely to respond to their targeted therapy AEZS-108. … READ MORE …

Calypso’s RT targeting technology to be acquired by Varian

According to an AP report on the Forbes web site this morning, Varian Medical Systems — perhaps the largest developer and manufacturer of radiation therapy equipment in the world — is to buy Calypso Medical Technologies. … READ MORE …